{"id":"NCT00547248","sponsor":"GlaxoSmithKline","briefTitle":"Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previously Primed With the Same Vaccines","officialTitle":"Booster Vaccination Course With the Pneumococcal Vaccine GSK 1024850A, DTPw-HBV/Hib and OPV or IPV in Children Who Completed the Primary Vaccination Course in Study 107007","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-10-22","primaryCompletion":"2008-05-10","completion":"2008-10-07","firstPosted":"2007-10-22","resultsPosted":"2019-01-14","lastUpdate":"2019-01-14"},"enrollment":756,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Infections, Streptococcal"],"interventions":[{"type":"BIOLOGICAL","name":"Synflorix","otherNames":["Pneumococcal conjugate vaccine GSK1024850A"]},{"type":"BIOLOGICAL","name":"Tritanrix-HepB","otherNames":["DTPw-HBV vaccine"]},{"type":"BIOLOGICAL","name":"Hiberix","otherNames":["Hib vaccine"]},{"type":"BIOLOGICAL","name":"Polio Sabin","otherNames":["OPV"]},{"type":"BIOLOGICAL","name":"Poliorix","otherNames":["IPV"]},{"type":"BIOLOGICAL","name":"Prevenar (Wyeth)","otherNames":["Pneumococcal conjugate vaccine"]}],"arms":[{"label":"Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group","type":"EXPERIMENTAL"},{"label":"Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group","type":"ACTIVE_COMPARATOR"},{"label":"Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group","type":"EXPERIMENTAL"},{"label":"Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this observer blind study is to assess the safety in terms of fever \\>39Â°C (rectal temperature) and the immunogenicity in terms of antibody response following a booster vaccination with pneumococcal vaccine GSK 1024850A at 12 to 18 months of age in children previously primed with the same vaccines including a pneumococcal conjugate vaccine co-administered with a diphtheria, tetanus, whole cell pertussis (DTPw)-combined vaccine and OPV or IPV vaccines. Subjects participating in this study should have received three doses of pneumococcal conjugate vaccine in the primary study.\n\nThis protocol posting deals with objectives \\& outcome measures of the booster phase. The objectives \\& outcome measures of the primary phase are presented in a separate protocol posting (NCT number = NCT00344318)","primaryOutcome":{"measure":"Number of Subjects Reporting Rectal Temperature Greater Than (>) the Cut-off","timeFrame":"Within the 4-day (Days 0-3) period after booster vaccination","effectByArm":[{"arm":"Synflorix Pooled Group","deltaMin":64,"sd":null},{"arm":"Prevenar Pooled Group","deltaMin":20,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"12 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":13},"locations":{"siteCount":7,"countries":["Philippines","Poland"]},"refs":{"pmids":["20980933"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":280},"commonTop":["Pain","Irritability","Pyrexia","Erythema","Somnolence"]}}